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ABSTRACT
Introduction: Infections caused by multidrugresistant (MDR), extensively drug-resistant
(XDR), and difficult-to-treat (DTR) Pseudomonas
aeruginosa are increasingly challenging to combat. Ceftolozane–tazobactam (C/T) is a novel blactam–b-lactamase inhibitor combination now
commonly used to treat MDR and XDR
P. aeruginosa. Lower respiratory tract infections
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(LRTIs) remain the most common source of
infection caused by MDR/XDR P. aeruginosa.
Comparative effectiveness studies to date have
been limited by the type of comparator agents
(i.e., aminoglycosides and polymyxins) and the
inclusion of multiple infection sources (i.e.,
urinary tract, abdominal, skin and soft tissue,
etc.).
Methods: We performed a multicenter, retrospective analysis of adults with LRTI caused by
MDR or XDR P. aeruginosa admitted from January 2014 to December 2019. We aimed to
compare clinical outcomes between patients
who received C/T (n = 118) versus best alternative therapy (n = 88). The primary outcome was
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clinical failure, defined as 30-day mortality and/
or an adverse drug reaction on antibiotic
therapy.
Results: Two hundred and six patients met
inclusion criteria. The C/T group had a significantly higher proportion of XDR P. aeruginosa
and ventilator-associated bacterial pneumonia
(VABP). After multivariable logistic regression,
C/T treatment was independently associated
with a 73.3% reduction in clinical failure compared to those who received best alternative
therapy (P \ 0.001). The number needed to
harm with best alternative therapy was 3.
Conclusion: Our results suggest that C/T is a
safe and effective therapeutic regimen for
patients with MDR and XDR P. aeruginosa LRTI.
Keywords: Ceftolozane–tazobactam;
HABP/
VABP; Multidrug resistance; Pneumonia;
Pseudomonas aeruginosa
Key Summary Points
Why carry out this study?
Multidrug-resistant (MDR) and extensively
drug-resistant (XDR) Pseudomonas
aeruginosa are serious public health
concerns. High mortality is associated
with lower respiratory tract infections
caused by MDR/XDR P. aeruginosa, which
may be due to the inconsistency of
treatment strategies used to combat these
infections.
This manuscript aims to compare the
clinical outcomes of patients with lower
respiratory tract infections caused by
MDR/XDR P. aeruginosa treated with
ceftolozane/tazobactam or best alternative
therapy.
What was learned from the study?
Treatment with ceftolozane/tazobactam
was associated with improved patient
outcomes compared to those who
received best alternative therapy.

These results confirm previous data
regarding the treatment of MDR/XDR
P. aeruginosa with ceftolozane/tazobactam
and support its utility in patients with
lower respiratory tract infection caused by
MDR/XDR P. aeruginosa.

INTRODUCTION
In 2019, over 1.2 million people died as a result
of antibiotic-resistant infections worldwide [1].
The number of deaths attributed to antimicrobial resistance is estimated to rise to 10 million
people by 2050, as projected in the Review on
Antimicrobial Resistance [2]. Pseudomonas
aeruginosa is of particular concern because of its
extraordinary capacity to develop resistance.
The respiratory tract is the most frequent
infectious source of multidrug-resistant (MDR)
and extensively drug-resistant (XDR) P. aeruginosa [3, 4]. MDR P. aeruginosa is defined as nonsusceptible to at least one agent in three or more
antimicrobial categories, and XDR is defined as
non-susceptible to at least one agent in all but
two or fewer categories [3]. Ceftolozane, a novel
fifth-generation antipseudomonal cephalosporin, has independent activity against MDR
P. aeruginosa and is formulated in combination
with tazobactam, a b-lactamase inhibitor [5].
Ceftolozane–tazobactam (C/T) gained US Food
and Drug Administration (FDA) approval for
hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) in June 2019,
following the results of the ASPECT-NP trial,
and has since become a preferred regimen in the
treatment of drug-resistant P. aeruginosa [5–7].
Newer agents have since become available for
the treatment of HABP/VABP caused by drugresistant
P. aeruginosa,
including
imipenem/cilastatin/relebactam and cefiderocol; however, these agents will not be covered in
this article because of their novelty and lack of
data associated with them.
Despite MDR/XDR P. aeruginosa having the
largest incidence in HABP/VABP infections,
clinical evidence supporting C/T for these
infections is sparse. ASPECT-NP is the only
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randomized controlled study examining the
safety and efficacy of C/T for patients with
HABP/VABP, and it demonstrated noninferiority of C/T to meropenem for Gram-negative
pathogens; however, MDR/XDR P. aeruginosa
was uncommon with only 50 patients (n = 34
C/T, n = 16 meropenem) in the microbiologic
intention-to-treat population [8]. Furthermore,
retrospective studies and case series have
demonstrated clinical success rates for C/T of
approximately 70–80% in patients with MDR
P. aeruginosa infections, but their results are
difficult to interpret because of inclusion of
multiple disease states with comparator agents
limited to aminoglycosides and/or polymyxins
[9, 10].
Polymyxins and aminoglycosides may
remain active against MDR/XDR isolates, but
are associated with a higher risk of nephrotoxicity compared to the novel agents [9]. As a
result of increased safety risks with aminoglycosides and polymyxins plus accessibility issues
to newer agents (i.e., shortages and high costs),
other traditional agents, such as meropenem
and cefepime, have been administered at high
doses as prolonged infusions to improve pharmacokinetic/pharmacodynamic (PK/PD) target
exposures against drug-resistant pathogens
[4, 11–13]. Combination therapy is another
therapeutic approach to combat MDR P. aeruginosa; however, a clear benefit has not been
demonstrated over monotherapy. The concept
of difficult-to-treat (DTR) P. aeruginosa was
introduced in 2018 and was defined by the
Infectious Diseases Society of America (IDSA) as
non-susceptibility to piperacillin–tazobactam,
ceftazidime, cefepime, aztreonam, meropenem,
imipenem–cilastatin, ciprofloxacin, and levofloxacin. According to the IDSA guidance on the
Treatment of Antimicrobial-Resistant GramNegative Infections, combination therapy
against DTR P. aeruginosa is not routinely recommended [14, 15]. Although the DTR definition is comprehensive, its use in retrospective
studies may be unrealistic because of limitations
in susceptibility reporting. Needless to say, gaps
remain within the IDSA guidance for treatment
of MDR/XDR/DTR P. aeruginosa, specifically
with regards to infection source. To address
these gaps, we conducted a multicenter,

retrospective cohort comparing safety and efficacy outcomes of patients with lower respiratory tract infection (LRTI) caused by MDR/XDR
P. aeruginosa treated with C/T or best alternative
therapy.

METHODS
Study Design and Population
We conducted a retrospective, observational
cohort at the Detroit Medical Center (DMC) and
Henry Ford Hospital (HFH) between 2014 and
2019. Cohorts included (1) patients who
received C/T for 48 h or more for the index
infection composed the C/T group; (2) best
alternative therapy group, which included
patients who received traditional beta-lactams
(piperacillin/tazobactam,
cefepime,
meropenem, ceftazidime, or ceftazidime/avibactam), aminoglycosides, and/or polymyxins.
Patients meeting the following criteria were
eligible for inclusion: (1) age 18 years or older;
(2) MDR or XDR P. aeruginosa isolated from at
least one of the following samples: sputum,
pleural fluid, tracheobronchial aspirate, or
bronchoalveolar lavage; (3) diagnosis of LRTI
defined as per Centers for Disease Control and
National Healthcare Safety Network (CDC/
NHSN) definitions [16, 17]. Patients with
known P. aeruginosa colonization (two positive
cultures at least 3 months apart over the course
of 12 months), cystic fibrosis, and those who
died or were discharged within 48 h of initiation of antimicrobials for empiric treatment of
LRTI were excluded [18]. Inhaled aminoglycosides or polymyxins were allowed in both study
arms. Patients with polymicrobial infections or
concomitant infections were included.
Outcomes
The primary outcome was composite clinical
failure, defined as 30-day all-cause mortality
and/or an adverse drug reaction (ADR) during
antibiotic therapy. Secondary endpoints included individual components of the composite
outcome, 30-day recurrence from end of
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antibiotic treatment for index infection, hospital length of stay, time to active therapy, and
30-day readmission from discharge date. Time
to active therapy was measured from index
respiratory culture collection.
Data Collection and Study Definitions
Relevant patient demographic, clinical, and
treatment data between 2014 to 2019 were
extracted from the electronic medical record
and entered into a secured electronic data collection form [19]. The Wayne State Institutional
Review Board (IRB) with Detroit Medical Center
research authorization approved the study
design and reporting, and waived the requirement for patient consent. Respiratory cultures
were processed at the DMC and HFH microbiology laboratories according to Clinical and
Laboratory Standards Institute (CLSI) procedures [20]. Bacterial identification and antimicrobial susceptibility testing were performed
using Microscan (Siemens Healthcare Diagnostics), Phoenix (BD), or Vitek2 (bioMérieux).
Clinical variables were collected on the basis of
medical team notes and microbiological/diagnostic reports. Occurrence of side effects was
collected on the basis of laboratory assessment
or notes by the medical team and assessed using
Common Terminology Criteria for Adverse
Events (CTCAE) definitions and the Naranjo
Adverse Drug Reaction Probability Scale
[21, 22]. ADRs must have been documented in
progress notes as related to the antibiotic(s) of
interest. Severity of illness and patient comorbidities were assessed using the Acute Physiology and Chronic Health Evaluation II
(APACHE II) score and Charlson comorbidity
index (CCI), respectively. APACHE II was assessed within 24 h of index respiratory infection.
LRTI was defined according to the CDC/NHSN
definitions and classified as hospital acquired if
the index respiratory culture was obtained more
than 48 h after admission [16]. Combination
therapy was defined as concomitant use of two
antimicrobials for at least 48 h for index infection. Active therapy was defined as in vitro
susceptibility for organism(s) recovered on culture. MDR P. aeruginosa was defined as non-

susceptible to at least one agent in three or more
antimicrobial categories, and XDR was defined
as non-susceptible to at least one agent in all
but two or fewer categories [3]. Thirty-day allcause mortality was defined as death from any
cause within 30 days of index respiratory culture collection. Nephrotoxicity, defined as a
serum creatinine increase of at least 0.5 mg/dL
or a 50% increase from baseline on two consecutive measurements during antibiotic therapy for the index infection, was evaluated in
patients not receiving hemodialysis or renal
replacement [23]. Those receiving hemodialysis
or renal replacement during antibiotic therapy
were considered as not having nephrotoxicity.
Statistical Analysis
Bivariate comparisons of baseline characteristics, infection-related variables, and outcomes
between patients treated with C/T and best
alternative therapy regimens were performed.
The chi-squared or Fisher’s exact test was utilized for categorical data, and the Student t test
or Mann–Whitney U test were used to compare
continuous parametric and nonparametric
variables, respectively. Multivariable logistic
regression was used to assess the independent
association between best alternative therapy
regimens and composite clinical failure while
adjusting for confounding variables. All variables associated with the primary composite
outcome of clinical failure in the bivariate
analysis at a P value of less than 0.1 and at least
10% variability (variables covering at least 10%
of total cases) were entered into the model
simultaneously and removed using a backward
stepwise approach. Covariates were retained in
the model if the P value for the likelihood ratio
test for their removal was less than 0.1. The
variance of inflation factor was used to assess
the multicollinearity of covariates in the model.
Variables with a variance of inflation factor
greater than 3 were not entered into the model.
The Hosmer–Lemeshow goodness-of-fit test was
used to assess the model’s fit. All tests were twotailed, with P values less than 0.05 considered
statistically significant. IBM SPSS software,
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version 28.0 (SPSS, Inc., Chicago, IL, USA), was
used for all calculations.

RESULTS
Participants
During the study period, 241 patients with
MDR/XDR P. aeruginosa LRTI were recorded. Of
these, 35 were excluded from the analyses
because of death or discharge within 48 h of
initiation of antimicrobials for empiric treatment of LRTI (n = 24), had known P. aeruginosa
colonization (n = 7) or cystic fibrosis (n = 4).
The remaining 206 patients with MDR/XDR
P. aeruginosa LRTI were included in the study
(C/T, n = 118; best alternative therapy, n = 88)
(Fig. 1).
Descriptive Data
Within the entire cohort there were 144 (69.9%)
men, the median age was 61.0 (53–72) years,
and the patients had a median (interquartile
range, IQR) APACHE II score of 24 (9–28). The
XDR phenotype was more common in the C/T
group (49.2% vs. 31.8%, P = 0.013) as was VABP
(52.5% vs. 38.6%, P = 0.048) compared to the
best alternative therapy group. The rate of
polymicrobial infection (39.8% vs. 44.3%,
P = 0.518) and acute kidney injury (AKI) on
admission (36.4% vs. 30.6%, P = 0.394) was
similar between groups. Among patients with
polymicrobial infections, Gram-positive organisms were more common in the C/T group
(6.8% vs. 18.6%, P = 0.014) whereas Gramnegative organisms Klebsiella pneumoniae

(15.9% vs. 5.1%, P = 0.009) and Stenotrophomonas maltophilia (11.4% vs. 5.9%,
P = 0.161) were more common in the best
alternative therapy group. Of those with susceptibility data available, most patients with
S. maltophilia (9/11, 81.8%) and K. pneumoniae
(12/12, 100%) received active therapy against
their respective organisms.
A comparison of baseline clinical characteristics between patients who received C/T for
48 h or more and those that received best
alternative therapy is shown in Table 1. Some
notable differences were observed between the
two groups. P. aeruginosa with an XDR phenotype was more common in the C/T group
compared with the best alternative therapy
group, 49.2% vs. 31.8% (P = 0.013); as well as
history of AKI, 29.7% vs. 17.0% (P = 0.037); and
dementia, 15.3% vs. 4.5% (P = 0.014), respectively. Conversely, neutropenia and tumor with
metastasis were more prominent in the best
alternative therapy group compared to the C/T
group, 19.3% vs. 0.0% (P \ 0.001) and 14.8%
vs. 2.5% (P = 0.001), respectively. Infection
characteristics and polymicrobial organisms are
also displayed in Table 1.
Treatment Data
Overall, 118 patients with MDR/XDR P. aeruginosa LRTI received C/T (57.3%). Eighty-eight
patients received best alternative therapy
(42.7%), among which cefepime (n = 45), meropenem (n = 35), and piperacillin–tazobactam
(n = 18) were the most common. Intravenous
polymyxins were utilized less frequently with
only 13 patients (6.3%) having received
polymyxin B and 10 patients (4.9%) received

Fig. 1 Flowchart of patients included in the study. MDR multidrug-resistant, XDR extensively drug-resistant, LRTI lower
respiratory tract infection, h hours, C/T ceftolozane–tazobactam
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Table 1 Baseline demographics and clinical characteristics of the cohort
Characteristics

C/T
(n = 118)

Best alternative
(n = 88)

All patients
(n = 206)

P value

Age in years, median (IQR)

61.0 (54–73)

63.5 (50–71)

61.0 (53–72)

0.894

Age over 60 years

60 (50.8)

48 (54.5)

108 (52.4)

0.599

Male sex

83 (70.3)

61 (69.3)

144 (69.9)

0.874

BMI, median (IQR)

25 (19–29)

24 (20–28)

24 (19–29)

0.733

XDR P. aeruginosa

58 (49.2)

28 (31.8)

86 (41.7)

0.013

African American

64 (54.2)

53 (60.2)

117 (56.8)

0.391

Caucasian

43 (36.4)

29 (33.0)

72 (35.0)

0.604

Hispanic

2 (1.7)

1 (1.1)

3 (1.5)

0.741

Asian

0 (0.0)

1 (1.1)

1 (0.5)

0.246

Other/unknown

9 (7.6)

4 (4.5)

13 (6.3)

0.368

Index culture collected in ICU

84 (71.2)

54 (61.4)

138 (67.0)

0.115

SOFA score, median (IQR)

6 (4–8)

6 (4–8)

6 (4–8)

0.926

APACHE II score, median (IQR)

25 (19–29)

23 (18–28)

24 (19–28)

0.403

CCI, median (IQR)

4 (2–6)

5 (3–7)

4 (2–7)

0.033

AKI present on admission

39 (36.4)

26 (30.6)

65 (31.6)

0.394

AKIN stage 1

23 (59.0)

14 (54.0)

37 (56.9)

AKIN stage 2

8 (20.5)

8 (31.0)

16 (24.6)

AKIN stage 3

8 (20.5)

4 (15.0)

12 (18.5)

Admission from NH/LTAC/SNF/
LTCF

44 (37.3)

29 (33.0)

73 (35.4)

0.52

COPD

37 (31.4)

33 (37.5)

70 (34.0)

0.357

Moderate to severe CKD

29 (24.6)

25 (28.4)

54 (26.2)

0.536

Chronic dialysis

12 (10.2)

8 (9.1)

20 (9.7)

0.796

Acute kidney injury

35 (29.7)

15 (17.0)

50 (24.3)

0.037

Myocardial infarction

7 (5.9)

3 (3.4)

10 (4.9)

0.405

Peripheral vascular disease

13 (11.0)

9 (10.2)

22 (10.7)

0.856

Heart failure

22 (18.6)

22 (25.0)

44 (21.4)

0.271

HIV

1 (0.8)

2 (2.3)

3 (1.5)

0.398

Demographics

Race

Severity of illness factors

Comorbid conditions
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Table 1 continued
Characteristics

C/T
(n = 118)

Best alternative
(n = 88)

All patients
(n = 206)

P value

Cerebrovascular disease

29 (24.6)

25 (28.4)

54 (26.2)

0.536

Dementia

18 (15.3)

4 (4.5)

22 (10.7)

0.014

Asthma

7 (5.9)

8 (9.1)

15 (7.3)

0.388

Connective tissue disease

12 (10.2)

7 (8.0)

19 (9.2)

0.587

Moderate or severe liver disease

2 (1.7)

1 (1.1)

3 (1.5)

0.741

Diabetes

18 (15.3)

16 (18.2)

34 (16.5)

0.576

Diabetes (with end-organ damage)

28 (23.7)

22 (25.0)

50 (24.3)

0.833

Hemiplegia

12 (10.2)

10 (11.4)

22 (10.7)

0.784

Tumor without metastasis

5 (4.2)

2 (2.3)

7 (3.4)

0.441

Tumor with metastasis

3 (2.5)

13 (14.8)

16 (7.8)

0.001

IV drug use

5 (4.2)

4 (4.5)

9 (4.4)

0.915

0 (0.0)

17 (19.3)

17 (8.3)

\ 0.001

1 (0.8)

0 (0.0)

1 (0.5)

0.387

3 (2.5)

7 (8.0)

10 (4.9)

0.074

3 (2.5)

2 (2.3)

5 (2.4)

0.901

83 (70.3)

53 (60.2)

136 (66.0)

0.13

71 (60.2)

58 (65.9)

129 (62.6)

0.4

41 (34.7)

41 (46.6)

82 (39.8)

0.086

11 (9.3)

7 (8.0)

18 (8.7)

0.731

4 (3.4)

2 (2.3)

6 (2.9)

0.637

9 (7.6)

10 (11.4)

19 (9.2)

0.359

VABP

62 (52.5)

34 (38.6)

96 (46.6)

0.048

Polymicrobial infections

47 (39.8)

39 (44.3)

86 (41.7)

0.518

Two organisms

31 (66.0)

30 (76.9)

61 (70.9)

0.224

Three organisms

14 (29.8)

9 (23.1)

23 (26.7)

0.712

Four organisms

2 (4.3)

0 (0.0)

2 (2.3)

0.508

4 (3.4)

6 (6.8)

10 (4.9)

0.257

Immunosuppression factors
Neutropeniaa
Solid organ transplant
Chemotherapy within 90 days

b

High dose corticosteroids
MDR risk factors
Antimicrobials within 90 daysb
Hospitalization within 90 days

b

Admitted from nursing home/LTCF
Chronic dialysis within last 30 days
Home wound care
Surgery within 30 days

b

b

Infection characteristics

Concomitant pathogens
Acinetobacter baumannii
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Table 1 continued
Characteristics

C/T
(n = 118)

Best alternative
(n = 88)

All patients
(n = 206)

P value

Citrobacter freundii

1 (0.8)

0 (0.0)

1 (0.5)

0.387

Enterobacter cloacae

1 (0.8)

0 (0.0)

1 (0.5)

0.387

Escherichia coli

2 (1.7)

3 (3.4)

5 (2.4)

0.429

Klebsiella oxytoca

1 (0.8)

0 (0.0)

1 (0.5)

0.387

Klebsiella pneumoniae

6 (5.1)

14 (15.9)

20 (9.7)

0.009

Morganella morganii

1 (0.8)

1 (1.1)

2 (1.0)

0.834

Proteus mirabilis

7 (5.9)

3 (3.4)

10 (4.9)

0.405

Providencia stuartii

9 (7.6)

5 (5.7)

14 (6.8)

0.583

Serratia marcescens

3 (2.5)

0 (0.0)

3 (2.5)

0.132

Stenotrophomonas maltophilia

7 (5.9)

10 (11.4)

17 (8.3)

0.161

Gram-positive bacteria

22 (18.6)

6 (6.8)

28 (13.6)

0.014

Fungal pathogen

1 (0.8)

0 (0.0)

1 (0.5)

0.387

Data are presented as number (%) unless stated otherwise
AIDS acquired immunodeﬁciency syndrome (CD4 \ 200), AKIN Acute Kidney Injury Network, APACHE Acute
Physiology and Chronic Health Evaluation, BMI body mass index, CCI Charlson comorbidity index, CKD chronic kidney
disease, COPD chronic obstructive pulmonary disorder, HIV human immunodeﬁciency virus, ICU intensive care unit, IQR
interquartile range, IV intravenous, LTAC long-term acute care facility, LTCF long-term care facility, MDR, multidrugresistant, moderate to severe CKD KDOQI CKD stage III–V or GFR \ 60 ml/min or on chronic dialysis, n number of
patients, NH nursing home, SNF skilled nursing facility, SOFA sequential organ failure assessment, VABP ventilatorassociated bacterial pneumonia (mechanically ventilated C 48 h prior to pneumonia diagnosis), XDR extensively drugresistant
a
Neutropenia deﬁned as absolute neutrophil count or white blood cell count \ 500
b
From time of index culture collection
colistin, and most of those patients received a
polymyxin for at least 48 h (14/23, 60.9%).
Intravenous aminoglycosides were administered in 59/206 patients (28.6%). In total,
48/206 patients (23.3%) received combination
therapy for at least 48 h. Interestingly, combination therapy was more common in the C/T
group (29.7%) compared to best alternative
therapy (14.8%) (P = 0.012). Of those cases
where C/T was used in combination with
another agent (n = 35), the most common
combination agents were aminoglycosides (22/
35) and polymyxins (8/35). Empiric therapy
with C/T was employed in eight patients (6.8%).
Most patients (88/118) received appropriate C/T

dosing, 3 g every 8 h, per package insert for
HABP/VABP, with a portion of patients receiving renally adjusted C/T dosing of 1.5 g every
8 h (15/118).
Resistance Data
Among the entire cohort, C/T susceptibilities
were available for most patients (61.7%). Of
those MDR/XDR P. aeruginosa isolates with
reported C/T susceptibility data, 87.4% were
susceptible to C/T (MIC B 4/4). Specifically,
27/31 (87.1%) were susceptible to C/T in the
best alternative therapy group, and 87/96
(90.6%) were susceptible in the C/T group. The
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Table 2 Antibiotic treatment and resistance data for the cohort
Characteristics

C/T (n = 118) Best alternative (n = 88) All patients (n = 206) P value

Antibiotics
Tobramycin

29 (24.6)

13 (14.8)

42 (20.4)

0.084

Amikacin

13 (11.0)

3 (3.4)

16 (7.8)

0.044

Gentamicin

1 (0.8)

0 (0.0)

1 (0.5)

0.387

Colistin

6 (5.1)

4 (4.5)

10 (4.9)

0.859

Polymyxin B

6 (5.1)

7 (8.0)

13 (6.3)

0.402

Cefepime

37 (31.4)

45 (51.1)

82 (39.8)

0.004

Meropenem

40 (33.9)

35 (39.8)

75 (36.4)

0.386

Piperacillin–tazobactam

22 (18.6)

18 (20.5)

40 (19.4)

0.745

Ceftazidime–avibactam

6 (5.1)

10 (11.4)

16 (7.8)

0.096

Aztreonam

1 (0.8)

5 (5.7)

6 (2.9)

0.041

Imipenem

1 (0.8)

1 (1.1)

2 (1.0)

0.834

Ceftazidime

0 (0.0)

2 (2.3)

2 (1.0)

0.1

Levoﬂoxacin

1 (0.8)

0 (0.0)

1 (0.5)

0.387

Inhaled antibiotics

23 (19.5)

15 (17.0)

38 (18.4)

0.654

Tobramycin

18 (15.3)

8 (9.1)

26 (12.6)

0.188

Colistin

7 (5.9)

8 (9.1)

15 (7.3)

0.388

23 (26.1)

72 (35.0)

0.022

Nephrotoxicity risk factors
Aminoglycoside or polymyxin C 48 h 49 (41.5)
Aminoglycoside C 48 h

21 (17.8)

8 (9.1)

29 (14.1)

0.076

Polymyxin C 48 h

9 (7.6)

5 (5.7)

14 (6.8)

0.583

35 (29.7)

13 (14.8)

48 (23.3)

0.012

Resistant to C/T (MIC C 16/4)

4 (4.2)

2 (6.5)

6 (4.8)

0.637

Intermediate to C/T (MIC 8/4)

5 (5.2)

2 (6.5)

7 (5.5)

0.701

Resistant C 1 carbapenem

97 (83.6)

63 (74.1)

160 (79.6)

0.099

Resistant C 1 aminoglycoside

16 (13.7)

7 (8.2)

23 (11.4)

0.241

Resistant C 1 polymyxin

9 (22.5)

5 (17.9)

14 (20.6)

0.641

Combination therapy
a

P. aeruginosa resistance

Data are presented as number (%) unless stated otherwise. Antibiotics are listed if patient received at least one dose
MIC minimum inhibitory concentration, C/T ceftolozane–tazobactam, h hours
a
Of those patients with resistance data available
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Table 3 Bivariate comparison of primary and secondary outcomes between patients with C/T and best alternative therapy
Outcomes

C/T (n = 118)

Best alternative (n = 88)

P value

28 (23.7)

43 (48.9)

\ 0.001

30-day mortality

18 (15.3)

18 (20.5)

0.331

Adverse drug reaction, any

12 (10.2)

29 (33.0)

\ 0.001

30-day recurrence

18 (15.3)

14 (15.9)

0.898

30-day readmission

21 (17.8)

13 (14.8)

0.563

60-day readmission

19 (16.1)

16 (45.7)

0.667

LOS from index culture, median (IQR)

23.1 (9.4–25.7)

10.3 (4.3–13.3)

\ 0.001

Discharge non-home

98 (56.6)

75 (43.4)

0.674

Time to active therapy, days

2.3 (0.3–4.0)

0.7 (- 0.9 to 2.6)

\ 0.001

Admitted to ICU during hospital stay

104 (88.1)

75 (85.2)

0.541

Multiple ICU admissions during hospital stay

27 (22.9)

11 (12.5)

0.057

Admitted to ICU (9 2)

19 (16.1)

9 (10.2)

0.224

Admitted to ICU (9 3)

8 (6.8)

2 (2.3)

0.137

ID consult

115 (97.5)

69 (78.4)

\ 0.001

Surgical consult

6 (5.1)

14 (15.9)

0.009

Surgical interventions

8 (6.8)

8 (9.1)

0.54

IV catheter removal

0 (0.0)

4 (4.5)

0.032

Incision and drainage

1 (0.8)

0 (0.0)

1

Debridement

3 (0.8)

2 (2.3)

1

Other

4 (3.4)

2 (2.3)

1

12 (10.2)

29 (33.0)

\ 0.001

6 (5.1)

12 (13.6)

0.032

5 (83.3)

5 (41.7)

0.152

Gastrointestinal (nausea, vomiting, diarrhea)

1 (0.8)

2 (2.3)

0.577

Cardiac (arrhythmias, QTc prolongation)

0 (0.0)

3 (3.4)

0.076

Lactic acidosis

0 (0.0)

6 (6.8)

0.005

Clostridioides difﬁcile infection

6 (5.1)

1 (1.1)

0.243

Encephalopathy (AMS or new onset seizures)

0 (0.0)

6 (6.8)

0.005

Hepatotoxicity (e.g., AST/ALT elevations)

2 (1.7)

0 (0.0)

0.508

Primary outcome
Composite clinical failure

Secondary outcomes

Adverse drug reactions
Nephrotoxicity

a

Nephrotoxin within 72 h

b
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Table 3 continued
Outcomes
Neutropeniac

C/T (n = 118)

Best alternative (n = 88)

P value

0 (0.0)

16 (18.2)

\ 0.001

Data are presented as number (%) unless stated otherwise
ALT alanine aminotransferase, AMS altered mental status, AST aspartate aminotransferase, h hours, ICU intensive care
unit, IQR interquartile range, LOS length of stay, QTc QT corrected for heart rate
a
Deﬁned as a serum creatinine increase C 0.5 mg/dL or a 50% increase from baseline on 2 consecutive measurements
during antibiotic therapy for the index infection
b
Receipt of aminoglycosides, amphotericin B, vancomycin, or IV contrast within 72 h timeframe of this nephrotoxicity
episode
c
ANC decrease to \ 1500 cells/mm3; or 50% decrease in ANC if baseline ANC \ 1500 cells/mm3 from initiation of
antibiotic
four patients with C/T-resistant isolates in the
C/T group were all treated with combination
therapy consisting of C/T plus another agent for
at least 48 h. Carbapenem resistance was evaluated in 201 patients with susceptibility information
and
carbapenem-resistant
(CR)
P. aeruginosa was found to be prevalent among
the cohort with 79.6% of isolates demonstrating resistance (MIC C 8) to at least one carbapenem (meropenem, imipenem–cilastatin, or
doripenem) (Table 2). The frequency of CRP. aeruginosa in the C/T group (97/116, 83.6%)
and best alternative therapy group (63/85,
74.1%) was assessed, although the difference in
frequency between groups was not statistically
significant (P = 0.099). Resistance to one or
more aminoglycosides was found in 11.4% of
patients with susceptibility information available (23/202) and there was no significant difference between C/T and best alternative
therapy groups, 13.7% vs. 8.2%, respectively
(P = 0.241). Resistance to polymyxins (MIC C 4
for polymyxin B or colistin) was 20.6% among
patients with susceptibility data (14/68) [20].
There was no statistically significant difference
in the frequency of polymyxin-resistant isolates
between C/T and best alternative therapy
groups, 22.5% and 17.9%, respectively
(P = 0.641) (Table 2).
Outcomes Data
A bivariate comparison of clinical outcomes
between C/T and best alternative therapy

patients is presented in Table 3. In bivariate
analysis, clinical failure was significantly higher
in the best alternative therapy group compared
to the C/T group, 48.9% vs. 23.7%, respectively
(P \ 0.001). The individual components of
composite clinical failure, i.e., ADR (33.0% vs.
10.2%, P \ 0.001) and 30-day mortality (20.5%
vs. 15.3%, P = 0.331), were also found to be
higher in the best alternative therapy group,
although 30-day mortality was not significantly
different between groups. Hospital length of
stay (LOS) was higher in the C/T group compared to the best alternative therapy group (23.1
vs. 10.3 days, P \ 0.001) although ICU admission was comparable between groups, 88.1% vs.
85.2%, respectively (P = 0.541). Among patients
with susceptibility information, time to active
therapy was significantly longer in the C/T
group compared to the best alternative therapy
group (2.3 vs. 0.7 days, P \ 0.001) although no
significant differences were found in microbiologic recurrence or readmission between groups
(Table 3). Overall, patients who received best
alternative therapy were more likely to experience ADRs, including nephrotoxicity (33.0% vs.
10.2%, P \ 0.001), encephalopathy (6.8% vs.
0%, P = 0.005), and neutropenia (16.0% vs. 0%,
P \ 0.001), respectively (Table 3).
A bivariate comparison of baseline criteria
between all patients with and without clinical
failure was assessed (Table S1 in the supplementary material). Notable variables with differences between the two groups at the
prespecified P value of less than 0.1 were
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Table 4 Multivariable logistic regression for factors independently associated with clinical failure
Variables

OR

P value

95% CI

aOR

P value

95% CI

C/T treatment group

0.326

\ 0.001

0.179–0.591

0.267

\ 0.001

0.140–0.507

APACHE II score

1.088

\ 0.001

1.042–1.137

1.102

\ 0.001

1.052–1.154

Variables included (1) treatment with C/T, (2) moderate-severe CKD, (3) APACHE II, (4) age over 60, (5) CCI, (6)
SOFA, (7) COPD, (8) tobramycin. Hosmer–Lemeshow goodness-of-ﬁt test P = 0.336; variance inﬂation factor B 3 for all
variables included at model entry
OR odds ratio, CI conﬁdence interval, aOR adjusted odds ratio, C/T ceftolozane–tazobactam

included in the stepwise selection process for
the multivariable logistic regression model. The
final model had an area under the receiver
operating characteristic (ROC) curve of 0.73,
indicating that successful classification of clinical failure was achieved with the fitted model.
The Hosmer–Lemeshow goodness-of-fit test
demonstrated an acceptable P value (P = 0.336).
Treatment with C/T was significantly associated
with a 73.3% lower likelihood of clinical failure
(adjusting for APACHE II) compared with best
alternative therapy (aOR 0.267, 95% CI
0.140–0.507, P \ 0.001). Independent associations between clinical failure and included
variables are listed in Table 4.

DISCUSSION
To our knowledge, this is the largest study to
date evaluating C/T for the treatment of MDR/
XDR P. aeruginosa LRTI. Further, this is the first
analysis to compare safety and efficacy outcomes of C/T vs. best alternative therapy
specifically for the treatment of MDR/XDR
P. aeruginosa LRTI. The population included was
largely critically ill, demonstrated by high
APACHE II scores and CCIs, ICU admission, and
VABP diagnoses. Susceptibility to C/T was consistent with previously reported susceptibility
rates in MDR/XDR P. aeruginosa (76.9–92.2%)
[20, 24, 25]. Although C/T demonstrates excellent activity against MDR/XDR P. aeruginosa, it
is important to consider the predominant, local
resistance mechanisms in order to apply
empirical therapy with C/T due to loss of
activity against K. pneumoniae carbapenemase
(KPC)
and
metallo-b-lactamases
[26].

Combination therapy with C/T was used in
nearly 30% of patients with a variety of agents
including colistin, polymyxin B, tobramycin,
amikacin, ciprofloxacin, and levofloxacin.
Interestingly, polymicrobial infection was not
associated with clinical failure during bivariate
comparison, likely owing to appropriate
administration of active therapy (Table S1 in
the supplementary material). After we controlled for confounders, C/T was associated with
a 73.3% reduction in clinical failure (P \ 0.001),
despite having longer time to active therapy
(2.3 vs. 0.7 days) and longer LOS (23.1 vs.
10.3 days), respectively. Greater incidence of
XDR P. aeruginosa and VABP in the C/T group
likely contributed towards longer time to active
therapy and LOS, respectively. These findings
are consistent with recent data in MDR/XDR
P. aeruginosa invasive infections, including
those outside of the respiratory tract (e.g., urinary tract and wound infections) that demonstrate improved outcomes with novel betalactam/beta-lactamase inhibitors (i.e., C/T and
CZA) compared to traditional regimens for the
management of MDR/XDR Gram-negative
infections [9]. While this retrospective analysis
cannot determine the true extent of clinical
failure risk in this complex, critically ill population, our results are clinically relevant because
treatment regimen was the only modifiable
factor contributing to significantly reduced
clinical failure after multivariable regression.
Unlike previous comparative effectiveness
studies, the present study includes meropenem,
among other traditional beta-lactam agents, for
the treatment of MDR/XDR P. aeruginosa, which
adds to the literature to support C/T over these
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traditional therapies. A recent retrospective
evaluation by Pogue et al. investigated the
impact of C/T vs. polymyxin or aminoglycoside-based regimens on clinical outcomes in
200 patients with drug-resistant P. aeruginosa
infections. Like the present analysis, the cohort
represented a complex patient population, with
69% of patients admitted to the ICU, a median
SOFA score of 8, and 63% mechanically ventilated at the onset of infection. The study compared rates of clinical cure, defined as resolution
of signs/symptoms of infection, between
patients who received C/T (n = 100) and polymyxin or aminoglycoside-based regimens
(n = 100). In their analysis, higher clinical cure
(P = 0.002) and lower AKI rates (P \ 0.001) were
demonstrated in patients receiving C/T compared to those who received polymyxin- or
aminoglycoside-based regimens [9]. However,
other commonly utilized monotherapy regimens (i.e., carbapenems, cefepime, etc.) were
not included, and other infection sites, including urinary tract and wound, comprised over
30% of the population. In response, Vena et al.
reported results from a multicenter, retrospective 1:2 matched case–control analysis of 48
patients with MDR/XDR P. aeruginosa HABP/
VABP or bloodstream infection [27]. Although
limited by small sample size, their findings
corroborated the results from Pogue et al. with
C/T-based regimens demonstrating a trend
towards higher cure rates and lower incidence
of AKI compared to colistin- or aminoglycosidebased regimens. Taken with the results of the
current study, these data support preferential
use of C/T over alternative therapy options for
MDR/XDR P. aeruginosa LRTIs.
Our study improves upon the previous
investigations by comparing all conventional
agents to C/T for the treatment MDR/XDR
P. aeruginosa, as opposed to only including
polymyxins and aminoglycosides as comparators. As demonstrated in our data, cefepime,
meropenem, and piperacillin–tazobactam are
still utilized in the treatment of MDR P. aeruginosa. As a result, our study has high external
validity by including a representative population with real-world treatment regimens. The
present study also includes detailed resistance
data, which allows us to describe the frequency

of MDR and XDR P. aeruginosa, further characterize the P. aeruginosa isolates, and improve
internal validity. Furthermore, by excluding
other disease states (i.e., bacteremia, urinary
tract, etc.) we are better able to extrapolate our
results with more precision to patients with
respiratory infection caused by MDR/XDR
P. aeruginosa.
There are several limitations to the present
study that should be considered. In addition to
the retrospective nature of data collection, the
P. aeruginosa respiratory culture data were collected from two centers in Michigan, and
therefore antibiotic formularies, patient populations, and institutional prescribing patterns
may affect the applicability of these results to
other institutions. Second, infectious disease
(ID) consultations, which have been associated
with improved outcomes in previous studies,
were more frequent in the C/T group than the
best alternative therapy group likely as a result
of antibiotic restriction tiers [28, 29]. When ID
consult was included as a study variable and was
considered as a component of C/T intervention
in the logistic regression, the results of the primary analysis remained unchanged. Lastly, an
inherent limitation exists within the composite
outcome, which includes nephrotoxicity, for
which a small portion of patients were ineligible
to achieve because of hemodialysis. However,
the proportion of patients with hemodialysis
was very similar between the C/T and best
alternative therapy groups (10.2% vs. 9.1%,
P = 0.796), and hemodialysis was not found to
be significantly different between those with
clinical failure and those without (11.3% and
7.4%, P = 0.351). Limiting the type of infection
to the lower respiratory tract narrows our analysis and including all antimicrobials represents
a real-world approach to treatment and outcomes in this complicated patient population.

CONCLUSION
Overall, we found that C/T-based regimens were
well tolerated and showed significant reduction
in clinical failure compared to best alternative
therapy regimens in patients with MDR/XDR
P. aeruginosa LRTI. Our study adds to the
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mounting evidence that C/T appears to be a safe
and effective therapy for treatment of LRTI
caused by MDR/XDR P. aeruginosa. Further
studies are needed to assess the impact of
combination therapy with C/T and other agents
on patient outcomes in those with severe
infection caused by drug-resistant P. aeruginosa.
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